Physician profile
Farqan Khan
NPI 1548646755
$3,407.00
in general payments reported to CMS, 2019-2025
10 companies · $975 in 2025
The $975 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $229 · 2022: $665 · 2023: $473 · 2024: $1,066 · 2025: $975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,513.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,631.66 | 2022-2025 | Apretude, Cabenuva, Dovato |
| Gilead Sciences, INC. | $1,074.61 | 2021-2025 | Descovy, Biktarvy, Sunlenca |
| Abbvie INC. | $293.11 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $236.50 | 2024-2025 | Pifeltro, Delstrigo |
| E.R. Squibb & Sons, L.L.C. | $42.68 | 2024-2025 | Cobenfy |
| Bayer Healthcare Pharmaceuticals INC. | $36.15 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.47 | 2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $24.55 | 2024 | Uzedy |
| Indivior INC. | $23.16 | 2025 | Sublocade |
| Lilly USA, LLC | $18.11 | 2024 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farqan Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.